The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.
- RIO’s Prof Sarah Fidler featured in a news piece celebrating 25 years of Imperial’s Faculty of Medicine and trailblazing HIV and AIDS research1st Dec 2022 by Genevieve Timmins, Imperial College London The launch of Imperial’s Faculty of Medicine in 1997 coincided with […]
- The RIO Trial on World AIDS Day1st December 2022 On this #WorldAIDSDay2022 we would like to thank all our participants for all their commitment and time […]
- Long-awaited results of the eCLEAR study are out showing the impact of the bNAb ‘3BNC117’ in people with detectable viraemia17 Oct 2022, Nature Medicine The eCLEAR study published their results in Nature Medicine in October. This study combined the […]
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.